Biomedical subjects

Douglas Nelson

Publications and source records attributed to Douglas Nelson.

5 recordsLinked to original sources

PubMed2006

Use of a pediatric observation unit for treatment of children with dehydration caused by gastroenteritis.

OBJECTIVE: Observation units (OUs) have emerged as a cost-saving alternative to traditional ward admission for many pediatric illnesses. Dehydration caused by gastroenteritis is a common reason for admission to a pediatric OU. In this study, we describe characteristics of patients with presumed gastroenteritis admitted to a pediatric OU and seek to identify factors associated with unplanned inpatient admission, defined as the inability to discharge an OU patient within 24 hours. METHODS: Retrospective cohort chart review with nested case-control study of children admitted to a pediatric OU from August 2000 to July 2001 for treatment of dehydration caused by vomiting or diarrhea from presumed gastroenteritis. Controls were defined as patients in the cohort who were successfully discharged within 24 hours from the OU; cases were defined as those requiring unplanned inpatient admission. RESULTS: Four hundred sixty-seven admissions were reviewed; 430 OU admissions involving 417 patients met criteria for inclusion. Patients' mean age was 1.8 years (median, 1.2 years), and 55% were boys. Patients presented with both diarrhea and vomiting in 77% of cases, and 72% had experienced symptoms for 48 hours before presentation. Nineteen percent of patients had temperatures greater than 38 degrees C; 25% had an anion gap of greater than 14; 37% had serum bicarbonate less than 15 mmol/L, and 10% had serum sodium less than 135 or greater than 145 mmol/L. Unplanned inpatient admission was required in 19% of patients. We found no significant association between specific historical, physical examination, and laboratory characteristics and need for an unplanned inpatient admission. CONCLUSION: Most patients with dehydration caused by gastroeneritis who need more treatment and observation than can reasonably be offered in an emergency department setting should be considered for OU admission regardless of their historical or laboratory characteristics.

Bicarbonates↗

PubMed2005

Colchicine treatment of alcoholic cirrhosis: a randomized, placebo-controlled clinical trial of patient survival.

BACKGROUND & AIMS: Colchicine improved survival and reversed cirrhosis in several small clinical trials. We compared the efficacy and safety of long-term colchicine, as compared with placebo, in patients with advanced alcoholic cirrhosis. METHODS: Five hundred forty-nine patients with advanced (Pugh B or C) alcoholic cirrhosis were randomized to receive either colchicine 0.6 mg twice per day (n = 274) or placebo (n = 275). Treatment lasted from 2 to 6 years. The primary outcome was all-cause mortality. Secondary outcomes were liver-related morbidity and mortality. Liver biopsy was requested prior to entry and after 24 months of treatment. RESULTS: Attendance at scheduled clinic visits and adherence with study medication were similar in colchicine and placebo groups. Alcohol intake was less than 1 drink per day in 69% of patients. In an intention-to-treat analysis, all-cause mortality was similar in colchicine (49%) and placebo (45%) patients (P = .371). Mortality attributed to liver disease was 32% in colchicine and 28% in placebo patients (P = .337). Fewer patients receiving colchicine developed hepatorenal syndrome. In 54 patients with repeat liver biopsies after 24 or more months of treatment, cirrhosis improved to septal fibrosis in 7 patients (3 colchicine, 4 placebo) and to portal fibrosis in 1 patient (colchicine). CONCLUSIONS: In patients with advanced alcoholic cirrhosis, colchicine does not reduce overall or liver-specific mortality. Liver histology improves to septal fibrosis in a minority of patients after 24 months of treatment, with similar rates of improvement in patients receiving placebo and colchicine. Colchicine is not recommended for patients with advanced alcoholic cirrhosis.

Colchicine↗

PubMed2005

The pediatric hybrid observation unit: an analysis of 6477 consecutive patient encounters.

OBJECTIVES: Pediatric observation units (OUs) are becoming more common in hospitals throughout the United States, providing physicians with a new disposition option for children who are judged to be too ill for home management. Some OUs function as "hybrid" units, serving both acutely ill and injured observation patients as well as scheduled elective procedure patients. How best to utilize this new resource is not yet defined. We studied the utilization of our pediatric hybrid OU during the first 2 years of operation to determine (1) the spectrum and frequency of diagnoses treated, (2) diagnoses and procedures most (and least) likely to attain discharge successfully within 24 hours, and (3) whether age was associated with inability to be discharged from the OU within 24 hours. METHODS: The study setting was a 20-bed hybrid OU located in a pediatric tertiary care hospital in Salt Lake City, Utah. The records of all patients admitted during the first 2 years of OU operation, from August 1999 through July 2001, were examined retrospectively. RESULTS: There were 6477 OU admissions: 4189 (65%) for acutely ill and injured observation patients and 2288 (35%) for scheduled elective procedure patients. For the observation patients, median age was 2.5 years and median length of stay was 15.5 hours. Common admission diagnoses in these patients included enteritis/dehydration (n = 722), orthopedic injuries (n = 362), asthma (n = 327), closed head injury (n = 289), urgent transfusion/infusion (n = 221), bronchiolitis (n = 212), croup (n = 207), abdominal pain (n = 199), cellulitis (n = 177), and nonfebrile seizure (n = 98). Overall, 15% of observation patients required subsequent inpatient admission for >24-hour stay. Observation diagnoses that were most likely to require inpatient admission were hematochezia (60%), viral pneumonia (46%), and bronchiolitis (43%). We demonstrated successful OU discharge rates (>85%) for several diagnoses not commonly reported: neonatal hyperbilirubinemia, aseptic meningitis, and diabetic ketoacidosis in the patient with known diabetes. Among the scheduled elective procedure patients, median age was 5.0 years and median length of stay was 3.0 hours. Only 1% of these patients required subsequent inpatient admission. In both populations, age < or =30 days was associated with increased need for inpatient admission, with a relative risk of 1.9 (95% confidence interval: 1.4-2.6) among the observation patients and 13.9 (95% confidence interval: 3.0-65.0) among scheduled procedure patients. CONCLUSION: Our pediatric hybrid OU played an important role in the treatment of children who were admitted for observation as a result of acute illness or injury, as well as children who required scheduled procedures. For both patient types, we identified diagnoses that are most and least likely to attain successful discharge within 24 hours. The majority (85%) of observation patients were discharged successfully within 24 hours. Successful discharge rates for diagnoses that are not commonly managed in other pediatric OUs were reported. We identified certain age groups within selected diagnoses that may not have been appropriate for the OU.

Adolescent↗

PubMed2002

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

PURPOSE: Patients with high-risk myelodysplastic syndrome (MDS) have high mortality from bone marrow failure or transformation to acute leukemia. Supportive care is standard therapy. We previously reported that azacitidine (Aza C) was active in patients with high-risk MDS. PATIENTS AND METHODS: A randomized controlled trial was undertaken in 191 patients with MDS to compare Aza C (75 mg/m(2)/d subcutaneously for 7 days every 28 days) with supportive care. MDS was defined by French-American-British criteria. New rigorous response criteria were applied. Both arms received transfusions and antibiotics as required. Patients in the supportive care arm whose disease worsened were permitted to cross over to Aza C. RESULTS: Responses occurred in 60% of patients on the Aza C arm (7% complete response, 16% partial response, 37% improved) compared with 5% (improved) receiving supportive care (P <.001). Median time to leukemic transformation or death was 21 months for Aza C versus 13 months for supportive care (P =.007). Transformation to acute myelogenous leukemia occurred as the first event in 15% of patients on the Aza C arm and in 38% receiving supportive care (P =.001). Eliminating the confounding effect of early cross-over to Aza C, a landmark analysis after 6 months showed median survival of an additional 18 months for Aza C and 11 months for supportive care (P =.03). Quality-of-life assessment found significant major advantages in physical function, symptoms, and psychological state for patients initially randomized to Aza C. CONCLUSION: Aza C treatment results in significantly higher response rates, improved quality of life, reduced risk of leukemic transformation, and improved survival compared with supportive care. Aza C provides a new treatment option that is superior to supportive care for patients with the MDS subtypes and specific entry criteria treated in this study.

Adult↗

PubMed2002

Colonoscopy and polypectomy.

Colonoscopy and polypectomy, when performed by adequately trained physicians, is a safe and effective procedure that can decrease deaths resulting from colorectal cancer.

Colonic Neoplasms↗